S&P 500 Futures
(0.65%) 5 115.25 points
Dow Jones Futures
(0.02%) 38 294 points
Nasdaq Futures
(0.82%) 17 711 points
Oil
(0.80%) $84.24
Gas
(-5.49%) $1.548
Gold
(0.67%) $2 358.30
Silver
(0.85%) $27.59
Platinum
(0.27%) $923.00
USD/EUR
(0.18%) $0.933
USD/NOK
(0.39%) $10.99
USD/GBP
(0.05%) $0.800
USD/RUB
(-0.37%) $91.83

Realtime updates for Uni-Bio Science Group [0690.HK]

Exchange: HKSE Sector: Healthcare Industry: Biotechnology
Last Updated26 Apr 2024 @ 03:59

7.59% HKD 0.0850

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 03:59):

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China...

Stats
Today's Volume 1.70M
Average Volume 5.96M
Market Cap 516.60M
EPS HKD0 ( 2023-08-28 )
Next earnings date ( HKD0 ) 2024-05-16
Last Dividend HKD0.00224 ( 2007-08-22 )
Next Dividend HKD0 ( N/A )
P/E 8.50
ATR14 HKD0.00100 (1.18%)

Uni-Bio Science Group Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Uni-Bio Science Group Financials

Annual 2023
Revenue: HKD484.72M
Gross Profit: HKD390.46M (80.55 %)
EPS: HKD0.0111
FY 2023
Revenue: HKD484.72M
Gross Profit: HKD390.46M (80.55 %)
EPS: HKD0.0111
FY 2022
Revenue: HKD440.32M
Gross Profit: HKD334.88M (76.06 %)
EPS: HKD0.00600
FY 2021
Revenue: HKD353.41M
Gross Profit: HKD277.01M (78.38 %)
EPS: HKD-0.00306

Financial Reports:

No articles found.

Uni-Bio Science Group Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)

Uni-Bio Science Group Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.32 - Potential for dividend initiation, but uncertain (13.67%)
Information
First Dividend HKD0.00224 2007-08-22
Last Dividend HKD0.00224 2007-08-22
Next Dividend HKD0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out HKD0.00224 --
Avg. Dividend % Per Year 0.00% --
Score 2.37 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.32
Div. Directional Score 7.86 --
Next Divdend (Est)
(2024-04-26)
HKD0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
2.37
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
2362.HK Ex Dividend Junior 2023-06-01 Annually 0 0.00%
1349.HK Ex Dividend Junior 2023-06-05 Annually 0 0.00%
0393.HK Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
6668.HK Ex Dividend Junior 2023-06-13 Annually 0 0.00%
1899.HK Ex Dividend Junior 2023-06-13 Annually 0 0.00%
0927.HK Ex Dividend Knight 2023-08-29 Semi-Annually 0 0.00%
0057.HK Ex Dividend Knight 2023-09-01 Semi-Annually 0 0.00%
2880.HK Ex Dividend Junior 2023-06-20 Annually 0 0.00%
1480.HK Ex Dividend Junior 2023-06-08 Sporadic 0 0.00%
0551.HK Ex Dividend Junior 2023-09-12 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1461.5007.0810.00[0 - 0.5]
returnOnAssetsTTM0.2591.2001.3561.628[0 - 0.3]
returnOnEquityTTM0.4411.5006.219.31[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM2.070.8004.633.70[1 - 3]
quickRatioTTM1.8700.8003.712.96[0.8 - 2.5]
cashRatioTTM1.1261.5004.867.28[0.2 - 2]
debtRatioTTM0.112-1.5008.14-10.00[0 - 0.6]
interestCoverageTTM139.391.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM0.01802.009.9910.00[0 - 30]
freeCashFlowPerShareTTM0.01802.009.9910.00[0 - 20]
debtEquityRatioTTM0.178-1.5009.29-10.00[0 - 2.5]
grossProfitMarginTTM0.8071.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM0.1501.0009.009.00[0.1 - 0.6]
cashFlowToDebtRatioTTM2.501.00010.0010.00[0.2 - 2]
assetTurnoverTTM1.7730.8001.5111.209[0.5 - 2]
Total Score11.41

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM4.731.0009.620[1 - 100]
returnOnEquityTTM0.4412.507.569.31[0.1 - 1.5]
freeCashFlowPerShareTTM0.01802.009.9910.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM0.01802.009.9910.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.001651.500-3.340[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1581.0008.560[0.1 - 0.5]
Total Score4.32

Uni-Bio Science Group

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators